Print Issue: October 01, 2007

High-Flux Hemodialysis Has Advantages

High-flux hemodialysis confers a definite survival advantage in high-risk patients compared with low-flux hemodialysis, according to results from a long-term, prospective trial presented here for the first time.

Taking Aim at Acute Kidney Injury

Acute kidney injury (AKI) is a complex disorder for which there is no uniform definition. AKI has been reported in up to 7% of hospitalized patients, but epidemiologic studies are sparse and confounded by differences in case definitions and heterogeneity in patient populations.

Novel Peptide-Based ESA Promising

BARCELONA—A novel peptide-based erythropoiesis-stimulating agent (ESA) called Hematide safely raises hemoglobin levels in anemic CKD patients and maintains stable hemoglobin levels in hemodialysis patients who switch to the drug from epoetin alfa, data suggest.

A Closer Look at Home Hemodialysis

As patients, physicians, dialysis providers, and payers search for more favorable outcomes in patients with end-stage renal disease (ESRD), alternative dialysis regimens have gained popularity. Among these therapies are dialysis treatments that are performed more frequently, for longer periods of time, and/or at the patient’s home.

Gadolinium Peril Confirmed

Scottish researchers have confirmed an association between gadolinium-based contrast agent use and development of nephrogenic systemic fibrosis (NSF) in patients with renal failure undergoing renal replacement therapy (RRT), according to a report in Radiology (2007; published online ahead of print).

Next post in FDA News